Market Cap 506.75B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 20.26
Forward PE 19.35
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 24,803,900
Avg Vol 9,122,028
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 42%
Beta 0.36
Analysts Strong Sell
Price Target $210.00

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
Suite510
Suite510 Dec. 20 at 12:23 PM
$JNJ $KVUE $SPX The boat is sinking again 😂 Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder Minnesota jury has awarded $65.5 million to a woman who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing mesothelioma ByThe Associated Press December 19, 2025, 8:38 PM
0 · Reply
OptionsWizzard
OptionsWizzard Dec. 20 at 5:50 AM
OptionWizards Tip (education only): Before trading options on MA, NFLX, or JNJ, review the company’s upcoming earnings dates to avoid unexpected volatility. $MA $NFLX $JNJ Not financial advice.
0 · Reply
clan
clan Dec. 20 at 12:24 AM
$MNKD All analysts' PTs for MNKD are much much higher than today's close. Do you see this, $JNJ $MRK $SNY ?
0 · Reply
3DBuilds
3DBuilds Dec. 19 at 11:27 PM
$CRBU $NTLA $EDIT $JNJ $BMY Amazing 🤩 Jennifer and Zuckerberg next year 💯 things are gunna get Amazing 🌎
0 · Reply
dudebob
dudebob Dec. 19 at 10:32 PM
Attn. pharma & battery/ev folks ‼️ Something is goin on with $KODK .. major end of day volume! # $JNJ $TSLA $TEVA $ABAT
0 · Reply
PickAlpha
PickAlpha Dec. 19 at 8:40 PM
PickAlpha Mid-Day — Trump locks in pharma price pacts President Trump said the White House reached pricing deals with nine drugmakers, taking the total to 14 of 17 targeted this summer. The agreements aim to cut prices for Medicaid, push direct-to-consumer discounted sales (via a planned TrumpRX site), and tie some new US launch prices closer to overseas levels — in exchange for a 3-year reprieve from threatened tariffs. Names cited include NVS / BMY / GILD / AMGN / GSK / SNY / MRK; holdouts: ABBV / JNJ / REGN. Our view is: this is policy-driven margin risk packaged as “tariff relief.” The market will reprice on how enforceable the confidential terms are and whether “MFN-style” pricing spreads beyond Medicaid/DTC into broader commercial channels. Near-term, the uncertainty premium rises for the remaining holdouts (they’re next in line), while “deal signers” get headline relief but face a multiple cap until the revenue/mix impact is quantified. Tickers $MRK $ABBV $JNJ
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 19 at 8:24 PM
Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $207.50 Put · DEC 26, 2025 Exp Entry Price: $1.50 - $1.58 Exit Price Target: $3.53 Profit Margin: +135% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PatrickPredictions
PatrickPredictions Dec. 19 at 8:04 PM
ARBB is a low float MONSTER!! retail momentum + 900k float = BOOM 💥 $TTD $SES $NBY $SBET $JNJ say
1 · Reply
th66
th66 Dec. 19 at 7:21 PM
$JNJ President Trump just mentioned jnj will have meeting next week
0 · Reply
staydowngetdown
staydowngetdown Dec. 19 at 7:00 PM
$ASBP IS NEXT 🚀 $TNXP $AQST $LLY $JNJ
0 · Reply
Latest News on JNJ
Final Trade: JNJ, NVO, UBER, BMY

Dec 15, 2025, 6:22 PM EST - 4 days ago

Final Trade: JNJ, NVO, UBER, BMY

BMY NVO UBER


US FDA grants priority voucher to J&J's blood cancer treatment

Dec 15, 2025, 10:39 AM EST - 4 days ago

US FDA grants priority voucher to J&J's blood cancer treatment


Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 11, 2025, 7:05 PM EST - 8 days ago

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations


16 Quality Stocks to Own for a Volatile Market

Dec 1, 2025, 1:23 PM EST - 18 days ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 21 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 21 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY


Wasatch Global Value Fund Q3 2025 Performance Review

Nov 28, 2025, 7:50 AM EST - 22 days ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA


Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:29 AM EST - 4 weeks ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion


Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:15 AM EST - 4 weeks ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson


Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 5 weeks ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY


Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 6 weeks ago

Johnson & Johnson: Dividends Don't Lie


Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 9:54 AM EST - 6 weeks ago

Cramer's Mad Dash: Johnson & Johnson


US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:34 AM EST - 6 weeks ago

US FDA expands use of J&J's Caplyta as add-on depression drug


Best Dividend Aristocrats For November 2025

Nov 1, 2025, 10:25 AM EDT - 7 weeks ago

Best Dividend Aristocrats For November 2025

ABBV ABT ADM ADP AMCR AOS ATO


Best Dividend Kings: October 2025

Oct 29, 2025, 5:11 AM EDT - 7 weeks ago

Best Dividend Kings: October 2025

ABBV ABM ABT ADM ADP AWR BDX


Suite510
Suite510 Dec. 20 at 12:23 PM
$JNJ $KVUE $SPX The boat is sinking again 😂 Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder Minnesota jury has awarded $65.5 million to a woman who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing mesothelioma ByThe Associated Press December 19, 2025, 8:38 PM
0 · Reply
OptionsWizzard
OptionsWizzard Dec. 20 at 5:50 AM
OptionWizards Tip (education only): Before trading options on MA, NFLX, or JNJ, review the company’s upcoming earnings dates to avoid unexpected volatility. $MA $NFLX $JNJ Not financial advice.
0 · Reply
clan
clan Dec. 20 at 12:24 AM
$MNKD All analysts' PTs for MNKD are much much higher than today's close. Do you see this, $JNJ $MRK $SNY ?
0 · Reply
3DBuilds
3DBuilds Dec. 19 at 11:27 PM
$CRBU $NTLA $EDIT $JNJ $BMY Amazing 🤩 Jennifer and Zuckerberg next year 💯 things are gunna get Amazing 🌎
0 · Reply
dudebob
dudebob Dec. 19 at 10:32 PM
Attn. pharma & battery/ev folks ‼️ Something is goin on with $KODK .. major end of day volume! # $JNJ $TSLA $TEVA $ABAT
0 · Reply
PickAlpha
PickAlpha Dec. 19 at 8:40 PM
PickAlpha Mid-Day — Trump locks in pharma price pacts President Trump said the White House reached pricing deals with nine drugmakers, taking the total to 14 of 17 targeted this summer. The agreements aim to cut prices for Medicaid, push direct-to-consumer discounted sales (via a planned TrumpRX site), and tie some new US launch prices closer to overseas levels — in exchange for a 3-year reprieve from threatened tariffs. Names cited include NVS / BMY / GILD / AMGN / GSK / SNY / MRK; holdouts: ABBV / JNJ / REGN. Our view is: this is policy-driven margin risk packaged as “tariff relief.” The market will reprice on how enforceable the confidential terms are and whether “MFN-style” pricing spreads beyond Medicaid/DTC into broader commercial channels. Near-term, the uncertainty premium rises for the remaining holdouts (they’re next in line), while “deal signers” get headline relief but face a multiple cap until the revenue/mix impact is quantified. Tickers $MRK $ABBV $JNJ
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 19 at 8:24 PM
Hedge Alert Live - Protect Your Portfolio Contract: $JNJ $207.50 Put · DEC 26, 2025 Exp Entry Price: $1.50 - $1.58 Exit Price Target: $3.53 Profit Margin: +135% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
PatrickPredictions
PatrickPredictions Dec. 19 at 8:04 PM
ARBB is a low float MONSTER!! retail momentum + 900k float = BOOM 💥 $TTD $SES $NBY $SBET $JNJ say
1 · Reply
th66
th66 Dec. 19 at 7:21 PM
$JNJ President Trump just mentioned jnj will have meeting next week
0 · Reply
staydowngetdown
staydowngetdown Dec. 19 at 7:00 PM
$ASBP IS NEXT 🚀 $TNXP $AQST $LLY $JNJ
0 · Reply
KingdomTrading
KingdomTrading Dec. 19 at 6:02 PM
$JNJ Current: $208.35 Entry: $216.38 Target: $502.40 Potential: +132.2% Horizon: 14 days The content provided on https://stocksurger.com/ is for informational purposes only and does not constitute a recommendation to buy or sell any security.
0 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 5:02 PM
Goldman Sachs has updated their rating for Johnson & Johnson ( $JNJ ) to Buy with a price target of 240.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:13 PM
Actionable Trade Alert for $JNJ: Market Context: $JNJ is currently trading at $208.31, showing a neutral RSI of 52.38, indicating no overbought or oversold conditions. The stock is above its 30-day moving average (MA30) of 202.33 and significantly above its 50-day moving average (MA50) of 197.45, suggesting a bullish short-term trend. Directional Bias: The price is closer to the 60D high of 215.19, which indicates potential upward momentum. The ATR of 3.88 suggests moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $208.50 - Stop Loss: $204.00 (risking $4.50, or about 2.16%) - Take Profit Targets: 1. $213.00 (target 1, approx. 2.5% gain) 2. $220.00 (target 2, approx. 5.5% gain) 3. $243.00 (target 3, approx. 16.6% gain) This plan offers a potential ROI of over 17% on target 3, aligning with the current market dynamics. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Dec. 19 at 12:40 PM
Consistent execution and cash flow make $JNJ a quiet defensive compounder
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 19 at 12:11 PM
$JNJ Current Stock Price: $208.31 Contracts to trade: $210 JNJ Dec 19 2025 Call Entry: $0.36 Exit: $0.47 ROI: 31% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
clan
clan Dec. 19 at 9:40 AM
$MNKD $PFE $JNJ @rooksleanne This vid is a hoot! "Die-beetus" RIP - Woolford 🇺🇸 1776 The video --> https://x.com/i/status/2001768673426489637
0 · Reply
ZacksResearch
ZacksResearch Dec. 19 at 6:00 AM
$JNJ just scored an FDA win — and it’s a big convenience upgrade for cancer treatment. 🚀 Johnson & Johnson received FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and improving convenience across NSCLC indications. See why this approval matters for JNJ here 👉 https://www.zacks.com/stock/news/2806390/jj-wins-fda-nod-for-subcutaneous-version-of-nsclc-drug-rybrevant?cid=sm-stocktwits-2-2806390-teaser-25509&ADID=SYND_STOCKTWITS_TWEET_2_2806390_TEASER_25509
0 · Reply
Floridahurricanehater
Floridahurricanehater Dec. 18 at 9:56 PM
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment - December 18, 2025 - Zacks.com $QQQ $JNJ $SPY $IBRX $2.09 IBRX with PT from analyst 6-24dollars. https://www.zacks.com/stock/news/2806268/3-cancer-stocks-to-buy-amid-rapid-advances-in-cancer-treatment
0 · Reply
DidYouReadThis
DidYouReadThis Dec. 18 at 9:30 PM
$REGN $JNJ $COR $OTLK For any pharma stock, what’s your estimate for guessing Europe vs USA earnings? Can you think of any examples that launched in Europe first? For example: guessing US might reach about 80% of Europe earnings, with a 6 month lag?
0 · Reply
RockyTSTH
RockyTSTH Dec. 18 at 7:42 PM
$JNJ FDA Approves J&J's New 5-Minute Injection For Lung Cancer
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 6:08 PM
$JNJ just scored an FDA win — and it’s a big convenience upgrade for cancer treatment. 🚀 Johnson & Johnson received FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and improving convenience across NSCLC indications. See why this approval matters for JNJ here 👉 https://www.zacks.com/stock/news/2806390/jj-wins-fda-nod-for-subcutaneous-version-of-nsclc-drug-rybrevant?cid=sm-stocktwits-2-2806390-teaser-25509&ADID=SYND_STOCKTWITS_TWEET_2_2806390_TEASER_25509
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 5:08 PM
FDA approval of $JNJ's Rybrevant Faspro: A game-changer in non-small cell lung cancer treatment? 🩺 🚀 Faster administration time (5 mins vs. 1 hour) for SC vs. IV 📈 Shares up more than 45% this year so far, far outpacing the industry’s 16% growth Discover how this could reshape the oncology landscape 👉 https://www.zacks.com/stock/news/2806390/jj-wins-fda-nod-for-subcutaneous-version-of-nsclc-drug-rybrevant?cid=sm-stocktwits-2-2806390-body-25506&ADID=SYND_STOCKTWITS_TWEET_2_2806390_BODY_25506
0 · Reply